TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17646601

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: UFH dosage of 5000 U 3 times daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: LMWH compared with UFH
Number of subjects: 36
Study: 16287388

Group type: EXPERIMENTAL
Intervention: Secular forgiveness condition
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Religious forgiveness condition
Number of subjects: 192

Group type: COMPARATOR
Intervention: No-intervention comparison condition
Number of subjects: 192
Study: 14607149

Group type: EXPERIMENTAL
Intervention: Facsimile Money
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real Money
Number of subjects: 0
Study: 10665629

Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐60 mg/day)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Clomipramine (50‐150 mg/day)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (12 sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 8690817

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours for 8 days) after a standardized 602-calorie, high-fat breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral ganciclovir (1000 mg every 8 hours for 8 days) after an overnight fast
Number of subjects: 20
Study: 2060542

Group type: EXPERIMENTAL
Intervention: Simvastatin 30 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6196822

Group type: EXPERIMENTAL
Intervention: Dextran 70 (1000-1500 ml) with Ringer's acetate solution (2000-3000 ml)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ringer's acetate alone (5000-8000 ml)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 23
Study: 3515137

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31895166

Group type: EXPERIMENTAL
Intervention: Regular statin users
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Nonregular statin users
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Hydrophilic statin users
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Lipophilic statin users
Number of subjects: 2664
Study: 27208982

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 500
Study: 24710972

Group type: EXPERIMENTAL
Intervention: Early sitting, standing, and walking in conjunction with contemporary Bobath approach (ECBA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Contemporary Bobath approach (CBA)
Number of subjects: 48
Study: 24085484

Group type: EXPERIMENTAL
Intervention: Thirst-driven fluid intake (TD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Programmed fluid intake (PFI)
Number of subjects: 10
Study: 20150565

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR) at 20% of 1-repetition maximum (1-RM) with pressure cuff inflated at 200 mmHg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (exercise without pressure cuff)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without blood flow restriction (Control)
Number of subjects: 7
Study: 18603750

Group type: EXPERIMENTAL
Intervention: isoflurane (Group B - BIS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: propofol (Group D - BIS)
Number of subjects: 40
Study: 16514531

Group type: EXPERIMENTAL
Intervention: CTAC scans
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: FDG-PET scans
Number of subjects: 107

Group type: COMPARATOR
Intervention: Diagnostic CT (gold standard)
Number of subjects: 107
Study: 12562048

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 1130

Group type: COMPARATOR
Intervention: 90 mg pamidronate
Number of subjects: 1130
Study: 9836092

Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Friendly visit (control)
Number of subjects: 256
Study: 8009935

Group type: EXPERIMENTAL
Intervention: baclofen
Number of subjects: 90

Group type: COMPARATOR
Intervention: sibazon
Number of subjects: 90

Group type: COMPARATOR
Intervention: amitriptylin
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 2492325

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA, 150 mg/8 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients with intracoronary thrombus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo in patients with intracoronary thrombus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients without thrombus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo in patients without thrombus
Number of subjects: 40
Study: 1085563

Group type: EXPERIMENTAL
Intervention: Total shunt (mesorenal H graft)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Selective distal splenorenal (Warren) shunt
Number of subjects: 46
Study: 31909482

Group type: EXPERIMENTAL
Intervention: Self-reported non-coeliac wheat sensitivity (SR-NCWS) in 2015 (13.8%; 95% CI, 12.0-15.8%)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Incident SR-NCWS reported between 2015 and 2018 (5.3% of respondents)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Gluten avoidance reported in 2018 (24.2% of respondents)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Participants with coeliac disease
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Participants with irritable bowel syndrome
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Participants with functional dyspepsia
Number of subjects: 1322
Study: 29978790

Group type: EXPERIMENTAL
Intervention: rESWT (radial extracorporeal shockwave therapy) for 1 cycle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local hormone injection for 1 cycle
Number of subjects: 40
Study: 26597879

Group type: EXPERIMENTAL
Intervention: Spiritual intervention (psychotherapy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (breast cancer patients without intervention)
Number of subjects: 90
Study: 25087182

Group type: EXPERIMENTAL
Intervention: Asparaginase and steroids
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Continuation of asparaginase and steroids
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Completion of ALL therapy
Number of subjects: 257
Study: 22659709

Group type: EXPERIMENTAL
Intervention: Educational program about HIV/AIDS (two days' observation and one-day workshop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (students from Shahid Beheshti University of Medical Sciences)
Number of subjects: 0
Study: 20636856

Group type: EXPERIMENTAL
Intervention: Magnetic film array application of 5% urea gel
Number of subjects: 17

Group type: COMPARATOR
Intervention: Passive occluded application of 5% urea gel with plastic occlusive film and non-magnetic film
Number of subjects: 17
Study: 19068713

Group type: EXPERIMENTAL
Intervention: Intentional segmentectomy for clinical T1NOM0 NSCLC of 2 cm or less
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediastinal lymph node dissection (MLND)
Number of subjects: 0
Study: 15745837

Group type: EXPERIMENTAL
Intervention: Postprandial strategy: premeal insulin lispro with basal insulin at bedtime (NPH insulin), targeting 2‐h PPBG < or = 7.5 mmol/l
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Basal strategy: insulin (NPH insulin twice daily or insulin glargine once daily; or premixed human insulin (70% NPH/30% regular; 30/70) twice daily), targeting fasting and premeal blood glucose (BG; < or = 6.7 mmol/l)
Number of subjects: 1355
Study: 12600854

Group type: EXPERIMENTAL
Intervention: Harris‐Benedict equation
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: FAO/WHO equation
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Energy intake adjustment
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Diet composition, sex, race, age, baseline weight
Number of subjects: 448
Study: 10427125

Group type: EXPERIMENTAL
Intervention: Genomic alterations detected by RLGS
Number of subjects: 21
Study: 7569821

Group type: EXPERIMENTAL
Intervention: Dependent in ADL
Number of subjects: 602

Group type: COMPARATOR
Intervention: Independent in ADL
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Sight impairment in men
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Dependence developed between ages 70 and 76
Number of subjects: 602
Study: 2268486

Group type: EXPERIMENTAL
Intervention: HD with a sodium profile (140‐148 mmol/L)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HD with a sodium profile and a variable UF rate (high‐low UF rate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional HD (dialysate sodium 140 mmol/L)
Number of subjects: 15
Study: 439926

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 263

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 263
Study: 31915861

Group type: EXPERIMENTAL
Intervention: 600 mg/day of CBD for 1 week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 32
Study: 31419355

Group type: EXPERIMENTAL
Intervention: Eligible patients for phase III trials
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Non-eligible patients for phase III trials
Number of subjects: 1267
Study: 29504579

Group type: EXPERIMENTAL
Intervention: Fibula fixation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 130
Study: 26706805

Group type: EXPERIMENTAL
Intervention: Conservative management (selective retrieval of macroscopic colorectal deep endometriosis nodules by bowel shaving and disc excision)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical approach (low large colorectal resection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative approach
Number of subjects: 0
Study: 25261342

Group type: EXPERIMENTAL
Intervention: Opioid antagonist (50 mg naltrexone)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both naltrexone and placebo after exercise
Number of subjects: 58
Study: 22492479

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6460
Study: 20443645

Group type: EXPERIMENTAL
Intervention: Sequential use of pharmacotherapy and psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical management and treatment as usual
Number of subjects: 0
Study: 17876994

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine, paroxetine, and sertraline (SSRIs available in Japan)
Number of subjects: 0
Study: 16128368

Group type: EXPERIMENTAL
Intervention: Aprotinin (15,000 KIU/min) administered in the pulmonary artery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12206997

Group type: EXPERIMENTAL
Intervention: Etomoxir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10566553

Group type: EXPERIMENTAL
Intervention: Serum RCP levels in breast cancer patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RCP assay for breast cancer detection
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RCP level > or = 1.0 ng/ml
Number of subjects: 52
Study: 8614913

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2006653

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7228648

Group type: EXPERIMENTAL
Intervention: Multiphasic screening (two screening sessions held about two years apart)
Number of subjects: 7229

Group type: COMPARATOR
Intervention: Conventional medical care (control group)
Number of subjects: 7229
Study: 31397125

Group type: EXPERIMENTAL
Intervention: Electroacupuncture preconditioning combined with induced urination
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine group (control)
Number of subjects: 80
Study: 27003595

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) over 3 months (12 weekly sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no specific LUTS treatment)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 31
Study: 27856482

Group type: EXPERIMENTAL
Intervention: 5-month training programme for nurses
Number of subjects: 34
Study: 24731890

Group type: EXPERIMENTAL
Intervention: 6-week stress management programme (relaxation breathing and progressive muscle relaxation, RB-PMR, twice a day) (N=31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not receiving the stress management programme) (N=29)
Number of subjects: 60
Study: 23208898

Group type: EXPERIMENTAL
Intervention: MRI plus MRS group
Number of subjects: 20

Group type: COMPARATOR
Intervention: MRI group
Number of subjects: 20
Study: 20655946

Group type: EXPERIMENTAL
Intervention: Project Towards No Drug Abuse (TND) program with regular workshop training
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Project Towards No Drug Abuse (TND) program with comprehensive implementation support
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 2538
Study: 17434541

Group type: EXPERIMENTAL
Intervention: 30 mg cinnarizine (CIN)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocculus Indicus 6CH (COC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study: 15865915

Group type: EXPERIMENTAL
Intervention: Low level white noise generators (NG)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 124
Study: 11956258

Group type: EXPERIMENTAL
Intervention: ECF (epirubicin 50 mg/m(2) every 3 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 200 mg/m(2)/d)
Number of subjects: 580

Group type: COMPARATOR
Intervention: MCF (mitomycin 7 mg/m(2) every 6 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 300 mg/m(2)/d)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: ECF
Number of subjects: 580

Group type: COMPARATOR
Intervention: MCF
Number of subjects: 580
Study: 9708225

Group type: EXPERIMENTAL
Intervention: 400 mg/day etidronate for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups received calcium and vitamin D supplementation
Number of subjects: 49
Study: 8374234

Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction (ICCE) with Choyce‐IX anterior chamber lens (ACL)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE) with posterior chamber lens (PCL)
Number of subjects: 65
Study: 2437556

Group type: EXPERIMENTAL
Intervention: Placenta eluted IgG
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Venoglobulins
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 113
Study: 29911321

Group type: EXPERIMENTAL
Intervention: Fractional CO2-laser treatment (two sessions in a 4-week interval)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated skin graft)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fractional CO2-laser treatment
Number of subjects: 26
Study: 28901116

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides combined with Danshen injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study: 25239537

Group type: EXPERIMENTAL
Intervention: Web-based Clinical Question Recorder
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Evidence Retrieval Coach (eight short educational videos)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Audit, Feedback and Gamification approach
Number of subjects: 904

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 904
Study: 23158080

Group type: EXPERIMENTAL
Intervention: Hygienic-dietary recommendations (active lifestyle recommendations)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study: 20137366

Group type: EXPERIMENTAL
Intervention: Bupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ropivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Levobupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 0.05% concentration of bupivacaine, ropivacaine, and levobupivacaine
Number of subjects: 450
Study: 17442997

Group type: EXPERIMENTAL
Intervention: FOLFOX4 with bevacizumab
Number of subjects: 829

Group type: COMPARATOR
Intervention: FOLFOX4 without bevacizumab
Number of subjects: 829

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 829
Study: 15604328

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 35
Study: 11948384

Group type: EXPERIMENTAL
Intervention: Mogen circumcision
Number of subjects: 59

Group type: COMPARATOR
Intervention: PlastiBell circumcision
Number of subjects: 59
Study: 10554373

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (24 hours)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Long-course antibiotic therapy (5 days)
Number of subjects: 63
Study: 8556837

Group type: EXPERIMENTAL
Intervention: Epoetin beta administered subcutaneously either daily or thrice weekly
Number of subjects: 266
Study: 1789812

Group type: EXPERIMENTAL
Intervention: Simvastatin (2.5 to 40 mg q.p.m.)
Number of subjects: 15
Study: 7326162

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia (75 micrograms kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incremental doses of papaveretum
Number of subjects: 0
Study: 31808268

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG connectivity metrics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG and fMRI
Number of subjects: 0
Study: 31229857

Group type: EXPERIMENTAL
Intervention: FEC-D (5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 103

Group type: COMPARATOR
Intervention: TC6 (docetaxel and cyclophosphamide)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: FEC-D
Number of subjects: 103

Group type: COMPARATOR
Intervention: TC6
Number of subjects: 103
Study: 28384752

Group type: EXPERIMENTAL
Intervention: Higher dose of NP001
Number of subjects: 394

Group type: COMPARATOR
Intervention: Normal baseline CRP receiving NP001 or placebo
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: CRP levels in independent cohort
Number of subjects: 394
Study: 26513587

Group type: COMPARATOR
Intervention: d-amphetamine (20mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: alcohol (0.8 g/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (THC) (7.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 23968797

Group type: EXPERIMENTAL
Intervention: DVD training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 75
Study: 21297491

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 19699834

Group type: EXPERIMENTAL
Intervention: Dietary intake among obese employees
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Mean daily energy intake
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Dietary fat recommendations compliance
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Fiber intake compliance
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Whole grains intake
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: MyPyramid recommendations compliance for fruits or vegetables
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: MyPyramid recommendations compliance for milk and dairy foods
Number of subjects: 373
Study: 18005291

Group type: EXPERIMENTAL
Intervention: Health library and information services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health sciences library research methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based library and information practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value and impact studies
Number of subjects: 0
Study: 15099130

Group type: EXPERIMENTAL
Intervention: Dual-process theory (DPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Signal-detection theory (SDT)
Number of subjects: 0
Study: 11230880

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0